Atropos Health, an AI clinical decision support company, raised a $33 million Series B led by Valtruis, an investment platform focused on value-based care (VBC).
Why it matters: Atropos claims its ChatRWD technology can eliminate hallucination risk, a primary concern for generative AI applications.
